PMID- 32518781
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2307-8960 (Print)
IS  - 2307-8960 (Electronic)
IS  - 2307-8960 (Linking)
VI  - 8
IP  - 10
DP  - 2020 May 26
TI  - Serum von Willebrand factor for early diagnosis of lung adenocarcinoma in 
      patients with type 2 diabetes mellitus.
PG  - 1916-1922
LID - 10.12998/wjcc.v8.i10.1916 [doi]
AB  - BACKGROUND: The elevation of plasma von Willebrand factor (vWF) has been proposed 
      to be a predictor of lung cancer. Type 2 diabetes mellitus (T2DM) causes 
      endothelial activation, resulting in the secretion of vWF. However, the role of 
      vWF in patients with T2DM complicated with lung cancer remains unclear. AIM: To 
      investigate the clinical value of serum vWF as a tumor marker in patients with 
      T2DM combined with lung adenocarcinoma in situ (AIS). METHODS: This study 
      enrolled 43 patients with T2DM combined with lung AIS (T2DM + AIS group), 43 
      patients with T2DM alone (T2DM group), 43 patients with lung AIS alone (AIS 
      group), and 43 healthy volunteers (control group). The serum levels of vWF, 
      insulin-like growth factor 1, and insulin-like growth factor binding protein 3 
      were determined. Multiple linear stepwise regression was performed to determine 
      the correlations among variables. RESULTS: Serum concentration of vWF in the T2DM 
      + AIS group was significantly higher than those in the T2DM, AIS, and control 
      groups (P < 0.05). Serum vWF levels in the T2DM and AIS groups were significantly 
      higher than that in the control group (P < 0.05). There was no significant 
      difference in serum vWF level between the T2DM and AIS groups. In the T2DM + AIS 
      group, serum vWF was independently associated and positively correlated with 
      serum levels of insulin-like growth factor 1 and insulin-like growth factor 
      binding protein 3 (P < 0.05). CONCLUSION: Serum vWF level may represent a novel 
      biomarker for the early diagnosis of lung AIS.
CI  - (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Zhou, Ying-Yi
AU  - Zhou YY
AD  - Department of Endocrinology, The First Affiliated Hospital of Soochow University, 
      Suzhou 215000, Jiangsu Province, China.
FAU - Du, Xuan
AU  - Du X
AD  - Department of Endocrinology, The First Affiliated Hospital of Soochow University, 
      Suzhou 215000, Jiangsu Province, China.
FAU - Tang, Jia-Li
AU  - Tang JL
AD  - Department of Endocrinology, The First Affiliated Hospital of Soochow University, 
      Suzhou 215000, Jiangsu Province, China.
FAU - Wang, Qiu-Ping
AU  - Wang QP
AD  - Department of Endocrinology, The First Affiliated Hospital of Soochow University, 
      Suzhou 215000, Jiangsu Province, China.
FAU - Chen, Ke
AU  - Chen K
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Soochow 
      University, Suzhou 215000, Jiangsu Province, China.
FAU - Shi, Bi-Min
AU  - Shi BM
AD  - Department of Endocrinology, The First Affiliated Hospital of Soochow University, 
      Suzhou 215000, Jiangsu Province, China. gtmake144523@163.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Clin Cases
JT  - World journal of clinical cases
JID - 101618806
PMC - PMC7262717
OTO - NOTNLM
OT  - Adenocarcinoma in situ
OT  - Correlation
OT  - Early diagnosis
OT  - Type 2 diabetes mellitus
OT  - von Willebrand factor
COIS- Conflict-of-interest statement: There are no conflicts of interest to report.
EDAT- 2020/06/11 06:00
MHDA- 2020/06/11 06:01
PMCR- 2020/05/26
CRDT- 2020/06/11 06:00
PHST- 2020/02/10 00:00 [received]
PHST- 2020/04/18 00:00 [revised]
PHST- 2020/04/24 00:00 [accepted]
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/06/11 06:01 [medline]
PHST- 2020/05/26 00:00 [pmc-release]
AID - 10.12998/wjcc.v8.i10.1916 [doi]
PST - ppublish
SO  - World J Clin Cases. 2020 May 26;8(10):1916-1922. doi: 10.12998/wjcc.v8.i10.1916.